102 articles with Medicenna
Medicenna Therapeutics Corp. ("Medicenna" or “Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended December 31, 2020.
Medicenna Hosting Key Opinion Leader Call on MDNA55 for the Treatment of Recurrent Glioblastoma Multiforme
- Call will take place on Friday, December 11, 2020 at 11:00 AM ET TORONTO and HOUSTON, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a key opinion leader (KOL) call on MDNA55 for the treatment of recurrent glioblastoma multiforme (rGBM) on Friday, December 11, 2020 at 11:00 AM ET.
Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA; TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended September 30, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted. “Over the last several months, we have achieved key clinical, regulatory, and corporate milestones that have left us well posit
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immuno-oncology company, today announced that Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna, will present at the Next-Gen Cytokine Therapeutics Summit, Stifel 2020 Virtual Healthcare Conference, as well as participate in the SVB Leerink Oncology 1x1 Day. All events are being held in November 2020. See below
Medicenna Presents Promising Preclinical Data on IL-2 and IL-13 Superkines at the EORTC-NCI-AACR Annual Meeting
-- Monotherapy and combination studies continue to demonstrate best - in - class potential of MDNA11 -- B ispecific IL-2/IL-13 Superkine demonstrates the potential to treat immunologically “cold” tumors
Medicenna Presents Late Breaking Abstract Updating Results from Phase 2b Recurrent GBM Trial at the 36th EORTC-NCI-AACR Meeting
Amongst an all-comer population, asingle treatment with MDNA55 resulted inat least 100%increase in both 12 month progression free survival (PFS-12 of 27% versus 2 to 10%) and 2-year survival (OS-24 of 20% vs 5 to10%) when compared to what is achieved with approved therapies
Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that it will be presenting two abstracts at the EORTC-NCI-AACR Virtual Scientific Program on Molecular Targets and Cancer Therapeutics to be held from October 24 - 25, 2020.
Medicenna Provides MDNA55 rGBM Clinical Program Update Following Positive End of Phase 2 Meeting with the U.S. Food and Drug Administration (FDA)
- After consultation with the FDA, the company can conduct a hybrid registration trial that allows for the use of matched external controls for two-thirds of control arm - - The design sets a new precedent for GBM clinical trials, allowing robust OS analysis and significantly reduces the number of trial participants randomized to standard of care therapies - - Reduced enrollment requirements in the control arm can substantially lower trial costs and expedite timelines for regulatory approval
Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference 2020, as well as participate in a fireside chat at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immuno-oncology company, today announced that the Company’s common shares have been approved for listing on The Nasdaq Capital Market (“Nasdaq”). Trading is expected to begin on Monday, August 24, 2020, under the symbol “MDNA” on the Nasdaq. The Corporation will retain its listing on the Toronto Stock Exchange under the symbol "MDNA" a
- Further advances in recurrent glioblastoma program including submission of End of Phase 2 (“EOP2”) meeting package for MDNA55 - EOP2 meeting scheduled for 29 th September, 2020 with FDA input expected in calendar Q4 2020 - Presented new preclinical data demonstrating the favorable safety profile and best-in-class potential of MDNA11 at ASCO 2020 - Depository Trust Certification (“DTC”) approved in July 2020 TORONTO and HOUSTON, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Medicenna Th
Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will present a corporate overview at the Raymond James 2020 Human Healthcare Innovation Conference on Thursday, June 18th, 2020, at 1:40 PM ET.
MDNA11, a long acting IL-2 super-agonist shows potent and durable tumor control with strong memory response in tumor models- -Up to 10-fold expansion of cancer-killing immune cells in non-human primates (NHP) without underlying safety issues or immunogenicity-
Tumor control achieved in 76% of evaluable subjects irrespective of IL4R expression resulting in mOS, mPFS and PFS-12 of 15.0 months, 4.6 months and 33%, respectively- -In the Proposed Population (all IL4R High subjects and IL4R Low subjects receiving high dose), mOS increased by up to 126% when compared to a Synthetic Control Arm (SCA)- TORONTO and HOUSTON , May 29, 202
Medicenna Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company, today announced its operational and financial results for the year ended March 31, 2020.
Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate Study
Conference call and webcast at 10:00AM EST to discuss MDNA19 results with pre-clinical experts showing robust immune responses without toxicity
Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control Arm
Medicenna Therapeutics Corp. announced that it has completed a retrospective study on subjects with recurrent Glioblastoma who matched eligibility requirements of subjects enrolled in the MDNA55-05 clinical trial.
Medicenna To Host Key Opinion Leader Call Focused on Latest MDNA55 Recurrent Glioblastoma Phase 2b Clinical Study Results
Medicenna Therapeutics Corp. announced that it will host a Key Opinion Leader call and webcast for the investment community on Monday, November 25, 2019 at 10:00 AM, ET.
Medicenna Announces Presentations on MDNA55 Recurrent Glioblastoma Clinical Trial at the Annual Meeting of the Society of Neuro-Oncology
Key Opinion Leaders Will Provide Updated Results on Efficacy, Safety and Delivery of MDNA55
Medicenna Presented Promising Preclinical Results from its IL-2 Superkine Platform at the 5th Annual International Cancer Immunotherapy Conference
Results show superiority and desired differentiation from competing IL-2 programs